| Filed On | Filing |
|---|---|
| 19 Aug 2026 | 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 11 Aug 2026 | 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure |
| 15 May 2026 | SCHEDULE 13G/A |
| 14 May 2026 | SCHEDULE 13G |
| 14 May 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 12 May 2026 |
8-K/A: Results of Operations and Financial Condition
London, May 12, 2026 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the first quarter ended March 31, 2026... |
| 12 May 2026 | 10-Q |
| 12 May 2026 | 8-K: Completion of Acquisition or Disposition of Assets |
| 09 Apr 2026 | ARS |
| 09 Apr 2026 | DEF 14A |
| 27 Mar 2026 | PRE 14A |
| 27 Mar 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 19 Mar 2026 | 10-K |
| 19 Mar 2026 | 8-K: Results of Operations and Financial Condition |
| 27 Feb 2026 |
Form 4: Jacquet Pierre, Director
Granted 66,000 Share Options (Right to buy) · Granted 106,848 Deferred Restricted Stock Units |
| 27 Feb 2026 |
Form 4: Yoskowitz Marc J, Director
Granted 66,000 Share Options (Right to buy) · Granted 96,163 Deferred Restricted Stock Units |
| 27 Feb 2026 |
Form 4: Shames Daniel, Director
Granted 66,000 Share Options (Right to buy) · Granted 96,163 Deferred Restricted Stock Units |
Loading...
